학술논문
A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma
Document Type
Article
Author
Source
In: BMC Cancer . (BMC Cancer, December 2021, 21(1))
Subject
Language
English
ISSN
14712407